Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study

References

• Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997;50:93–9.
   PubMedGoogle Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V. European Association of Urology (EAU) guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–7.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Petrylak DP. Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer. Curr Oncol Rep 2006;8:213–20.
   PubMedGoogle Scholar
• Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632–42.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 2008;179:906–10.
   PubMed Web of Science ®Google Scholar
• Picchio M, Castellucci P. Clinical indications of C-choline PET/CT in prostate cancer patients with biochemical relapse. Theranostics 2012;2:313–17.
   PubMed Web of Science ®Google Scholar
• Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415–19.
   PubMedGoogle Scholar
• De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002;42:18–23.
   PubMed Web of Science ®Google Scholar
• Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, et al. 18F-choline and/or (11)C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (< 1 ng/mL) after radical prostatectomy. BJU Int 2007;99:1415–20.
   PubMed Web of Science ®Google Scholar
• Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, et al. Relationship between PSA kinetics and [(18)F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012;39:271–82.
   PubMedGoogle Scholar
• Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18–23.
   PubMed Web of Science ®Google Scholar
• Porta M. editor. A dictionary of epidemiology. 5th ed. New York: Oxford University Press; 2008.
   Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168–72.
   PubMed Web of Science ®Google Scholar
• Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.
   PubMed Web of Science ®Google Scholar
• Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998;160:2418–24.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876–81; erratum 166:1839.
   PubMed Web of Science ®Google Scholar
• Eade TN, Guo L, Forde E, Vaux K, Vass J, Hunt P, et al. Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy. BJU Int 2012;109:1655–60.
   PubMedGoogle Scholar
• Bayley A, Rosewall T, Craig T, Bristow R, Chung P, Gospodarowicz M, et al. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;77:477–83.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–83.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122–50S.
   PubMed Web of Science ®Google Scholar
• Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, et al. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med 2012;37:325–31.
   PubMedGoogle Scholar
• Beam CA. Analysis of clustered data in receiver operating characteristic studies. Stat Methods Med Res 1998;7:324–36.
   PubMedGoogle Scholar
• Darwish OM, Raj GV. Management of biochemical recurrence after primary localized therapy for prostate cancer. Front Oncol 2012;2:48.
   PubMedGoogle Scholar
• Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of (11)C-choline positron emission tomography in recurrent prostate cancer. World J Urol 2013;31:319–23.
   PubMed Web of Science ®Google Scholar
• Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394–400.
   PubMed Web of Science ®Google Scholar
• Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39:13–26.
   PubMed Web of Science ®Google Scholar